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Introduction 
The heart and the vascular system are frequent and 
characteristic targets of several systemic 
autoimmune diseases1. The connective tissue 
diseases, which include systemic lupus 
erythematosus (SLE), rheumatoid arthritis (RA), 
ankylosing spondylitis (AKS), scleroderma, 
polymyositis and dermatomyositis, and mixed 
connective tissue disease (MCTD), are the systemic 
illnesses that most commonly affect the heart. 
Although these autoimmune-mediated 
inflammatory diseases predominantly affect the 
musculoskeletal system, the associated heart 
disease is an important cause of morbidity and 
mortality. The reported prevalence rates of heart 
disease in these conditions vary widely because of 
differences in patient characteristics, preselection 
bias, variability in the definition of cardiovascular 
abnormalities, and differences in the diagnostic 
methods used2. A second group of autoimmune 
disorders that can affect the heart are the vasculitis 
syndromes, some of which are rare in childhood 
and all of which are still poorly understood in terms 
of pathogenesis3. In this review we will describe the 
cardiac manifestations of the more common of 
these disorders in children. 
I. Autoimmune Connective Tissue Diseases 
Systemic Lupus Erythematosus (SLE) 
SLE is an autoimmune multisystem disorder of 
unknown etiology4, affecting between 1 and 6 in 
100,000 children5. In 20% of cases, the onset of 
SLE is seen before 16 years of age6. The diagnosis 
of SLE is made when 4 out of the 11 criteria, 
defined by the American Rheumatology 
Association, are met4. SLE has an overall mortality 
of more than 20% at 10 years. Heart disease is one 
of the most common causes of death of SLE 
patients2.  
Pericardial involvement is the most frequent 
cardiac affection in SLE 7, occurring at some point 
in over half of the patients with active SLE 8. In 
most of these patients, the pericardial involvement 
is clinically silent and benign in course. Pericardial 
tamponade can occur, and the differential diagnosis 
should then include infection and uremia 9.  
The prevalence of valvular disease in SLE in post-
mortem studies has ranged from 13% to 100% 2.Its 
pathogenesis is believed to be due to immune 
complex deposition and complement activation, 
leading to an acute, chronic, or recurrent 
inflammation of the valve leaflets. The presence in 
the leaflets of immune complexes, complement, 
antinuclear antibodies, lupus erythematosus cells, 
and hematoxylin bodies support this theory 10. 
Transesophageal echocardiography is more 
sensitive in detecting valvular lesions in SLE than 
transthoracic echocardiography. Valvular 
regurgitation, usually mild, is the most common 
valvular affection occurring in up to 79%. The 
mitral valve is most commonly affected, followed 
by the tricuspid, aortic and pulmonary valves.  
Libman-Sacks endocarditis is almost exclusively 
seen on the mitral and aortic valves. The masses are 
usually less than 1 cm2 in size with irregular 
borders and heterogenous echodensity but no 
independent motion. They can be located on any 
portion of the valve, on the atrial surface of the 
mitral valve, and the arterial surface of the aortic 
valve. Abnormal valve thickening also affects the 
left sided valves and is usually generalized, 
although it can predominate on the mid and tip 
portions. It is commonly associated with valvular 
regurgitation, valve masses or both. Valve stenosis 
and involvement of the annular or subvalvular 
apparatus are rare2. A unique feature of SLE is that 
valvular abnormalities frequently resolve (24%), 
appear de novo (12%), or persist but change over 
time (40%). The mortality at 5 years in patients 
with SLE and heart disease is about 20% and is 
predominantly related to valvular disease11. 
Infective endocarditis can be the initial presentation 
of valvular disease in some patients. Flares of SLE 
requiring high- dose steroids and cytotoxics 
frequently precede or accompany infection. Patients 
with SLE should probably receive antibiotic 
prophylaxis against infective endocarditis prior to 
any dental or nonsterile procedures. Additionally, 
prophylactic antiplatelet therapy should be 
considered in patients with SLE as valvular lesions 
can serve as a substrate for cardioembolism2. 
Pulmonary hypertension may occur in patients 
with SLE, and may precede its onset by several 
years12. Pulmonary hypertension in SLE may be 
due to pneumonitis, vasculitis, thromboembolism, 
or thrombosis in situ. Frank vasculitis is quite rare, 




idiopathic pulmonary hypertension13. Myocarditis 
can occur in patients with SLE, and can progress to 
arrhythmias and heart failure7. The association 
between T cell proliferation and myocarditis in 
patients with SLE suggests a role for a cellular 
mechanism in its pathogenesis14. Accelerated 
atherosclerosis is a recognized feature of SLE, 
reflecting a high prevalence of conventional risk 
factors, long-term corticosteroid use, and the 
presence of antiphospholipid antibodies. 
Additionally, mechanisms directly related to SLE 
may stimulate premature vascular disease in view 
of the fundamental role of inflammation in 
atherogenesis and recent epidemiologic 
observations associating markers of inflammation 
with prevalent atherosclerosis and incident 
cardiovascular disease. Roman et al15 noted a 
striking increase in the presence of underlying 
atherosclerotic and myocardial disease in the setting 
of SLE compared with a studied control population 
that was not dependent on an excess of 
conventional risk factors for atherosclerosis and LV 
hypertrophy. A rare cardiovascular manifestation of 
SLE, reported in only 15 cases, is aortic dissection. 
These patients were all young, had systemic 
disease; were mostly hypertensive, and had 
received corticosteroids for a relatively long period 
of time16. 
Neonatal Lupus Erythematosus (NLE) 
NLE is a model of passively acquired autoimmune 
disease where pathogenic antibodies are 
transplacentally acquired by the fetus17. Mothers 
may have SLE, Sjőrgen syndrome, or other 
connective tissue disease, or may be completely 
healthy at the time of delivery18. Cimaz et al19 
reported that the presence of anti Ro with or 
without anti-La autoantibodies, rather than the type 
of maternal autoimmune disease, is a risk factor for 
the development of NLE. The most important, 
irreversible and severe clinical manifestation of 
NLE is congenital complete heart block (CCHB) 
which occured in 1.6% of prospectively studied 
pregnancies of mothers with positive anti-Ro and/or 
anti-La autoantibodies, and caries a significant risk 
of morbidity and mortality. Other cardiac features 
of NLE include congenital malformations and less 
severe conduction abnormalities, notably 
prolonged QT interval19. Monitoring for fetal 
bradycardia due to CCHB during high risk 
pregnancies is recommended by weekly fetal 
echocardiograms between 18 and 24 weeks 
gestation. Prenatal therapy with steroids and 
plasmapheresis has yielded mixed results. Postnatal 
therapy involves cardiac pacing in two-thirds of 
surviving infants4.  
Juvenile Rheumatoid Arthritis (JRA) 
JRA is the most common rheumatic disorder of 
childhood and is classified into pauciarticular, 
polyarticular and systemic forms20. It is also further 
subdivided into rheumatoid factor positive or 
negative21. Clinical evidence of cardiac 
involvement in JRA is uncommon22. A diffuse, non 
specific fibrinous pericarditis occurs in 50% of 
patients with RA but is clinically silent, although 
sizeable effusions can occur22. Chronic 
symptomatic pericarditis can also occur and may 
require steroid therapy23. Valvular disease 
associated with RA is usually subclinical, and 
includes valvular thickening, valvular granulomas, 
and valvular regurgitation. Its incidence is variable 
but is more common in patients with erosive 
polyarticular and nodular disease, systemic 
vasculitis and high serum titers of rheumatoid 
factor. Valvular granulomas are unique to the 
disease, and resemble rheumatoid nodules. They are 
more commonly seen on the basal portions of the 
leaflets, are single, and the surrounding leaflet has 
an unremarkable appearance and mobility. Data 
suggest no association of valvular disease with age, 
duration of RA, or peripheral nodular disease2, 24. 
Pulmonary hypertension has been described in RA, 
most commonly due to interstitial fibrosis with 
medial thickening and intimal proliferation. Small 
and medium-sized PA vasculitis is rare but may 
occur in the absence of significant parenchymal 
lung disease and portends a grave prognosis13. 
Cardiovascular mortality accounts for almost half 
the deaths in RA, mainly due to ischemic heart 
disease (IHD)25. Studies in RA have indicated 
accelerated carotid atherosclerosis26. In RA, the 
primary site of inflammation is the synovial tissue 
from which cytokines can be released into the 
systemic circulation. These circulating cytokines 
can alter the function of distant tissues and generate 
a spectrum of proatherogenic changes that include 
insulin resistance, a characteristic dyslipidemia, 
prothrombotic effects, pro-oxidative stress, and 
endothelial dysfunction. Premature mortality in RA, 
largely due to cardiovascular disease, is related to 
the number of inflamed joints27. 
Juvenile Dermatomyositis/Polymyositis/Mixed 
Connective Tissue Disease (MCTD) 
Although Juvenile dermatomyositis is the most 
common myopathy of childhood, it affects only 3 
children per million per year28 between the ages of 
4 and 10 years4. Myocarditis and pericarditis are 
the most common forms of heart disease associated 
with this group of disorders. Coronary artery 
disease, conduction disturbances, valvular disease 
and pulmonary hypertension are uncommon2. 
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Mitral valve prolapse can be found in up to 50% of 
patients but no other specific valvular disease has 
been reported29. The myocardium in 
dermatomyositis may show loss of striations, 
fragmentation, and vascularization of muscle fibres 
with interstitial swelling and edema30. Although 
pulmonary hypertension is rare, when it does occur, 
it appears to be associated with a high mortality31. 
Scleroderma  
Scleroderma is a multisystem disease of unknown 
etiology that extends from a benign localized 
scleroderma to severe progressive systemic 
sclerosis, which can be fatal. Childhood 
scleroderma is rare with linear scleroderma being 
the common form in childhood4. Clinically overt 
heart disease occurs in 25% of patients and includes 
coronary artery disease, myocarditis, pericarditis, 
pulmonary and systemic hypertension, and less 
commonly, valvular heart disease, arrhythmias, 
and conduction abnormalities. Heart disease is the 
third major cause of death in these patients due to 
ischemic heart disease, heart failure, sudden death 
and pericarditis2. In primary systemic sclerosis of 
the heart, a myocardial fibrosis occurs that bears no 
direct relation to large or small vessel occlusion or 
any other anatomic abnormality, and tends to be 
patchy, involving all levels of the myocardium32. 
The morphologic characteristics of the myocardial 
lesions of primary cardiac systemic sclerosis are 
consistent with a Raynaud’s phenomenon of the 
heart33. The prevalence of pulmonary arterial 
hypertension (PAH) has been reported to be higher 
among patients with limited cutaneous sclerosis 
than among those with diffuse systemic sclerosis34. 
Antiendothelial cell antibodies (AECA) may be an 
important marker for disease severity in 
scleroderma, with one study demonstrating that the 
incidence of PAH was higher in patients with 
AECA than in those without the antibody35. 
Pericardial disease in systemic sclerosis is usually 
clinically silent and benign, with an incidence of 
40% as detected by echocardiography, especially in 
patients with diffuse disease. Large effusions, 
however, may carry a grave prognosis. Histology of 
the pericardium has been characterized by 
leukocytoclastic vasculitis34. 
Ankylosing Spondylitis (AKS) 
AKS, an HLA-B27 related autoimmune disease, is 
characterized by inflammation of the vertebral and 
sacroiliac joints, peripheral arthritis and anterior 
uveitis. AKS affects the heart predominantly in the 
form of valvular and aortic root disease and 
conduction disturbances with a prevalence of less 
than 10%. The valvular disease can precede other 
clinical manifestations of AKS. The valvular and 
aortic root disease associated with AKS results in 
cusp thickening and retraction, thickening of the 
aorto-mitral junction (subaortic bump), proximal 
aortitis resulting in aortic root thickening and 
dilation and aortic and mitral regurgitation. 
Complicating infective endocarditis can occur in 
patients with no known or subclinical disease, and 
both prophylactic antibiotic therapy for infective 
endocarditis and prophylactic antithrombotic 
therapy should be considered in these patients2. 
 
II. Vasculitis Syndromes 
Primary vasculitis is rare in children with an overall 
estimated annual incidence among children under 
17 years of age of 20.4/100 00036. 
Kawasaki Disease (KD) 
Although KD is classified as a vasculitis, unlike 
other inflammatory conditions of blood vessels, it is 
a self-limited condition, with fever and 
manifestations of acute inflammation lasting for an 
average of 12 days without therapy37. It is 
diagnosed by clinical criteria (Table 1)38, not 
histology or angiography. It is almost entirely a 
disease of children, with 80% to 90% of cases 
occurring before the fifth birthday. Death can occur 
in up to 1.5% of untreated children. Many aspects 
of KD suggest that it is caused by a transmissible 
agent3. 
The cardiovascular involvement in Kawasaki 
disease can be extensive.  Kato et al,39 reported a 
review of 1438 cases and found transient coronary 
artery dilatation in 28%, coronary artery 
aneurysm (Figure 1 and 2) in 18%, and other 
arterial aneurysms in 2%.  Other cardiac 
involvement included myocarditis in > 50%, 
pericarditis/effusion in 18%, myocardial infarction 
in 1.4%, mitral regurgitation in 0.9%, and aortic 
regurgitation in 0.2%.  Risk factors for the 
development of coronary artery aneurysm include 
prolonged or recurrent fever, white males, age less 
than one year, elevated white blood cell count and 
CRP level, and increased levels of cytokines 
including interleukin, TNF, and elevated beta 








Table 1. Criteria for the diagnosis of Kawasaki disease (KD)3. 
 
Fever lasting 5 days or more (4 days if treatment with IVIG eradicates fever) plus at least four of the following clinical 
signs not explained by another disease process (numbers in parentheses indicate the approximate percentage of children 
with KD who display the criterion): 
1. Bilateral conjunctival injection (80-90%) 
2. Changes in the oropharyngeal mucous membranes (including one or more of the following symptoms: injected 
or fissured lips, strawberry tongue, injected pharynx) (80-90%) 
3. Changes in the peripheral extremities, including erythema or edema of the hands and feet (acute phase) or 
periungal desquamation (convalescent phase) (80%) 
4. Polymorphous rash, primarily truncal; nonvesicular (90%) 
5. Cervical lymphadenopathy: anterior cervical lymph node at least 1.5cm in diameter (50%) 
IVIG: intravenous immunoglobulin; KD: Kawasaki disease 
 
  
Figure 1. Dilated left anterior descending and left 
circumflex coronary arteries with aneurysm 
formation and a thrombus in the left anterior 
descending coronary artery seen on transthoracic 
echocardiography (short axis parasternal view). 
Courtesy of Prof. Maiy H. Elsayed, Professor of 
Cardiology, Faculty of Medicine, Ain Shams 
University, Egypt. 
Figure 2. Selective coronary angiography showing 
saccular aneurysms of the branches of the left 
coronary artery. Courtesy of Prof. Maiy H. Elsayed, 
Professor of Cardiology, Faculty of Medicine, Ain 




Table 2: Treatment of acute Kawasaki disease (KD) 53 
Intravenous gamma globulin (IVGG) 
• 2g/kg as single infusion over 12 hours; should be given within 10 days of onset of fever 
Acetylsalicylic acid (ASA) 
• 80-100 mg/kg, divided into 4 doses, until patient is afebrile, then 3-5 mg/kg every day for 6-8 weeks* 
Evidence based guidelines do not exist for the management of patient sin the following situations: 
• Patients who are afebrile at the time of the presentation:  
o IVGG usually not recommended; give low dose ASA 
• Patients with persistent or recurrent fever after the initial dose of IVGG 
o May repeat IVGG dose or give intravenous corticosteroid therapy 
• Patients with evidence of myocarditis (i.e. diminished ventricular function; ventricular arrhythmia) 
o Supportive therapy, may give intravenous corticosteroid therapy or repeat IVGG 
 
* If varicella or influenza develops, ASA therapy should be stopped to reduce the risk of  
Reye’s syndrome. Discontinue ASA therapy 6-8 weeks after onset of illness if no coronary artery aneurysms are 
observed on follow up echocardiography 
 
IVGG: intravenous gamma globulin; ASA Acetyl Salicylic Acid 
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Kato, et al42 followed a cohort of 594 consecutive 
children for 10–21 years. Coronary aneurysms were 
present in 25%. Patients with normal findings at the 
first study did not develop future cardiac findings. 
Coronary aneurysms showed regression in 55%, but 
by 10–21 years later, 28 had stenosis within the 
coronary aneurysm, with myocardial infarction 
occurring in 11, 5 of whom died.  Stenosis 
developed in 12 of the 26 patients with giant 
aneurysms and no regression occurred.  Systemic 
artery aneurysms developed in 13 patients (2%), 
and valvular disease appeared in 7 (1.2%). The 
pathologic mechanisms of regression of aneurysms 
include marked thickening of the intima, which is 
rich in smooth muscle cells, in vessels that resume a 
calibre similar to normal vessels  If massive 
thrombosis occurred, there is more calcification, 
fissuring, deposition of protein like material, and 
hyaline degeneration, similar to athero-
sclerosis43,44,45.  
The wall motion abnormalities associated with 
ischemia during the early phases of KD can show 
significant improvement with time because of 
canalization and development of collateral vessels. 
Collateral vessel development is significantly 
correlated with a younger age at onset of KD, 
especially in patients with segmental rather than 
localized stenoses46. 
Cellular infiltration and edema in the myocardium 
are found frequently in postmortem examination of 
patients who died within 30 days from onset of KD 
47. Tissue from myocardial biopsies performed one 
month to 11 years after onset showed varying 
degrees of cellular infiltration, fibrosis, and 
abnormal myocyte structure48. The severity of 
myocarditis is not necessarily linked with the 
presence of coronary artery dilatation and IVIG has 
been shown to improve function49. Mild valvulitis 
assessed by mild regurgitation by Doppler 
echocardiography is very frequent in the acute 
phase, but severe valvulitis leading to persistent 
significant regurgitation is rare (~ 1 %).  Severe 
valvulitis can occur in patients with mildly dilated 
or normal appearing coronary arteries or may be 
due to ischemic papillary muscle dysfunction50. 
Aneurysms of the aorta and non-coronary 
medium size muscular arteries have been reported 
and need serial evaluation51. Arrhythmias, both 
tachy- and bradyarrhythmias, can occur during the 
acute phase of KD.  Late ventricular arrhythmia is 
usually associated with significant coronary 
occlusion52. The treatment of KD is outlined in 
Table 2. 
 
Polyarteritis Nodosa (PAN) 
PAN is a systemic necrotizing vasculitis with 
aneurysm formation affecting medium or small 
arteries3. Pediatric PAN is quite rare and when it 
does occur before adulthood, PAN incidence peaks 
at 9 to 10 years of age, and may be slightly more 
common in boys than in girls54. Systemic PAN may 
involve virtually any muscular artery. 
Consequently, in addition to constitutional 
symptoms, it may cause a vast array of organ 
dysfunction. Coronary arteritis may be seen at 
presentation or during the course of the disease55. 
Treatment usually aims at decreasing systemic 
vascular inflammation, mainly with high-dose 
steroid and other immunosuppressive agents. 
Recent reviews of PAN in children suggest an 
excellent overall prognosis, with a 4-year mortality 
rate under 5%54. 
Takayasu arteritis (TA) 
TA is the third most common form of childhood 
vasculitis56. The cause of TA remains unknown, 
although a primarily T-cell–mediated mechanism is 
suggested57. TA lesions consist of granulomatous 
changes progressing from the vascular adventitia to 
the media58 and its diagnosis is based on the 
distribution of involvement—primarily the aorta 
and its branches—and the young age of patients, 
typically below 40 years59. Onset of TA is most 
commonly during the third decade of life, but 
childhood disease has been reported as early as the 
first year of life60. In a recent review of childhood 
TA, the mean age of onset was 11.4 years, and two 
thirds of the patients were female61. Signs and 
symptoms included hypertension, cardiomegaly, 
elevated ESR, fever, fatigue, palpitations, vomiting, 
nodules, abdominal pain, arthralgia, claudication, 
weight loss, and chest pain. Angiography has been 
the standard method used for diagnosis. as the size 
of the vessels involved and the spotty nature of the 
vascular inflammation make biopsies impractical. 
In recent years, CT and MR angiograms have 
proven to be as useful and far less invasive, with 
MRI having the added advantage of revealing 
evidence of ongoing vessel wall inflammation. This 
information is particularly helpful because of the 
need to suppress the vasculitis completely to 
prevent disease progression, and because laboratory 
markers may be entirely normal despite ongoing 
inflammation62. Steroids and immunosuppressive 
agents used in other vasculitides have shown 
variable efficacy in TA. A recent report in adults 
documented a high response rate to TNF-
inhibitors63. Before starting such treatment, 
however, it is important to test patients for 
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tuberculosis, because aortitis is associated with 
mycobacterial infections64. 
 
III. Rheumatic Fever (RF) 
RF is the most frequent rheumatic disease and the 
main cause of acquired cardiac disease during 
childhood and adolescence in developing 
countries65. A sizeable body of evidence supports 
the role for the group A β-hemolytic streptococcus 
in the etiology of RF. There have been several 
hypothesis to explain a streptococcal pathogenesis 
for RF, the most feasible being the concept of 
antigenic mimicry in association with an abnormal 
immune response. A role of human host genetic or 
acquired variability in susceptibility to RF has also 
been demonstrated66 but studies of HLA and the B-
lymphocyte antigen D8/17 have not yielded results 
that can be utilized to identify susceptible 
individuals67. RF occurs mainly between the ages of 
5 and 15 years, but can occur in children who are 
younger than 5 years68. Recent data suggests that 
almost 90% of those who get RF develop rheumatic 
heart disease (RHD)67. Cardiac involvement, the 
only manifestation capable of causing death or 
leaving long-term sequelae, usually presents as a 
pancarditis and appears during the first three weeks 
after the onset of the disease. The patient complains 
of fatigue, anorexia, and may present with chest 
pain and dyspnea. Myocarditis is common and may 
evolve into congestive heart failure. It is usually 
associated with valvulitis. The mitral valves are 
most often affected, and the simultaneous 
involvement of mitral and aortic valves is also 
common. Isolated pericarditis in RF is rare and 
suggests a different diagnosis, such as JRA or 
SLE65. Primary prevention aims at identifying and 
treating streptococcal sore throat, while secondary 
prevention aims at preventing further attacks of RF 
by preventing the occurrence of streptococcal sore 
throat. Both have proved difficult to implement at a 
community level, and some authors believe that 
primary prevention will only be feasible if an 
antistreptococcal vaccine becomes available67. 
 
Summary 
Cardiac disease is a recognized and important 
consequence of most autoimmune diseases of 
childhood.  Its prevalence and severity is variable 
among the different disorders, and among patients 
suffering from the same disease. The factors 
influencing the development of heart disease in 
these are still not fully understood, but it is a major 
cause of morbidity and mortality in all of them. 
Early recognition of cardiac affection in children 
suffering from autoimmune disorders may improve 
patient outcome and further research is warranted 
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